Sarepta Therapeutics, Inc. (SRPT) Expected to Announce Quarterly Sales of $37.78 Million
Analysts predict that Sarepta Therapeutics, Inc. (NASDAQ:SRPT) will report sales of $37.78 million for the current fiscal quarter, Zacks reports. Six analysts have made estimates for Sarepta Therapeutics’ earnings, with the lowest sales estimate coming in at $36.50 million and the highest estimate coming in at $39.38 million. The firm is scheduled to issue its next earnings results on Thursday, October 26th.
On average, analysts expect that Sarepta Therapeutics will report full-year sales of $37.78 million for the current year, with estimates ranging from $129.70 million to $145.80 million. For the next year, analysts forecast that the business will post sales of $255.39 million per share, with estimates ranging from $196.51 million to $300.00 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Sarepta Therapeutics.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.46. The business had revenue of $35.01 million during the quarter, compared to the consensus estimate of $22.52 million. During the same quarter last year, the firm posted ($1.19) earnings per share. Sarepta Therapeutics’s revenue was up 350000.0% compared to the same quarter last year.
Several equities analysts have recently issued reports on the company. Royal Bank Of Canada assumed coverage on Sarepta Therapeutics in a research note on Friday. They set a “positive” rating on the stock. Cowen and Company reaffirmed an “outperform” rating and set a $69.00 price target on shares of Sarepta Therapeutics in a research note on Thursday. SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $56.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, September 7th. William Blair reaffirmed an “outperform” rating on shares of Sarepta Therapeutics in a research note on Thursday, September 7th. Finally, BidaskClub lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Nine investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. Sarepta Therapeutics currently has an average rating of “Buy” and a consensus target price of $62.31.
Shares of Sarepta Therapeutics (NASDAQ SRPT) traded up 1.21% during midday trading on Friday, reaching $46.75. 633,957 shares of the company’s stock traded hands. The firm’s market capitalization is $3.01 billion. The stock’s 50 day moving average price is $39.55 and its 200 day moving average price is $34.58. Sarepta Therapeutics has a 52-week low of $26.26 and a 52-week high of $63.73.
In related news, SVP Alexander Cumbo sold 5,918 shares of the stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $41.00, for a total transaction of $242,638.00. Following the completion of the transaction, the senior vice president now directly owns 22,793 shares in the company, valued at $934,513. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Shamim Ruff sold 12,138 shares of the stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $42.97, for a total value of $521,569.86. Following the transaction, the senior vice president now owns 27,312 shares of the company’s stock, valued at $1,173,596.64. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 78,056 shares of company stock valued at $3,224,208. 9.60% of the stock is owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of SRPT. Prentiss Smith & Co. Inc. grew its stake in Sarepta Therapeutics by 772.2% in the second quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock valued at $121,000 after purchasing an additional 3,166 shares in the last quarter. Ameritas Investment Partners Inc. acquired a new stake in shares of Sarepta Therapeutics in the first quarter valued at approximately $127,000. PNC Financial Services Group Inc. lifted its position in shares of Sarepta Therapeutics by 150.1% in the first quarter. PNC Financial Services Group Inc. now owns 4,666 shares of the biotechnology company’s stock valued at $138,000 after buying an additional 2,800 shares during the last quarter. Cubist Systematic Strategies LLC lifted its position in shares of Sarepta Therapeutics by 116.4% in the second quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock valued at $155,000 after buying an additional 2,474 shares during the last quarter. Finally, Edge Wealth Management LLC acquired a new stake in shares of Sarepta Therapeutics in the second quarter valued at approximately $175,000. Hedge funds and other institutional investors own 65.43% of the company’s stock.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.